Estrone and 17.BETA.-Estradiol Reverse Breast Cancer Resistance Protein-mediated Multidrug Resistance.
|
Accession number;02A0357257
|
| Title;Estrone and 17.BETA.-Estradiol Reverse Breast Cancer Resistance Protein-mediated Multidrug Resistance. |
| Author;
IMAI Y
(Japanese Foundation For Cancer Res., Tokyo)
TSUKAHARA S
(Japanese Foundation For Cancer Res., Tokyo)
ISHIKAWA E
(Japanese Foundation For Cancer Res., Tokyo)
TSURUO T
(Japanese Foundation For Cancer Res., Tokyo)
SUGIMOTO Y
(Japanese Foundation For Cancer Res., Tokyo)
|
Journal Title;Jpn J Cancer Res
|
Journal Code:F0633A
|
ISSN:0910-5050
|
|
VOL.93;NO.3;PAGE.231-235(2002)
|
| Figure&Table&Reference;FIG.3, TBL.2, REF.16 |
| Pub. Country;Japan |
| Language;English |
| Abstract;Breast cancer resistance protein (BCRP), an adenosine triphosphate-binding cassette transporter, confers resistance to a series of anticancer reagents, including mitoxantrone, SN-38 and topotecan. In the present study, we found that estrone and 17.BETA.-estradiol potentiated the cytotoxicity of mitoxantrone, SN-38 and topotecan in BCRP-transduced K562 cells (K562/BCRP). These estrogens showed only a marginal effect, or none, in parental K562 cells. Estrone and 17.BETA.-estradiol increased the cellular accumulation of topotecan in K562/BCRP cells, but not in K562 cells, suggesting that these estrogens inhibit the BCRP-mediated drug efflux and overcome drug resistance. (author abst.) |
|
|
|
Related Articles;
|
|
|
